Guide

Mounjaro vs Zepbound: Same Molecule, Different Rules

Identical active molecule, identical manufacturer, different approved indication. Mounjaro is licensed for type 2 diabetes and Zepbound for chronic weight management and

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

Identical active molecule, identical manufacturer, different approved indication. Mounjaro is licensed for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnoea. The difference decides which savings card you can use, and diabetes coverage is far more common than obesity coverage.

Answer last reviewed: 2026-08-03

What is actually different?

Mounjaro against Zepbound
Field	Mounjaro	Zepbound
Active molecule	Tirzepatide	Tirzepatide — identical
Approved indication	Type 2 diabetes	Chronic weight management; obstructive sleep apnoea with obesity
Dose range	2.5–15 mg	2.5–15 mg
Savings card	Diabetes card, commonly ~$25	Weight-management card, ~$25 if the plan covers it
Coverage likelihood	High — most plans cover diabetes drugs	Lower — many plans exclude obesity drugs
Self-pay vials	Not the primary channel	$299–$449 via LillyDirect

The practical consequence

The molecule is not the variable. The indication on the box is.

If you have a type 2 diabetes diagnosis, the diabetes route is usually far easier to get covered, because most plans cover diabetes drugs and a large share still exclude obesity medications outright.

If you do not have that diagnosis, Mounjaro is not the cheaper path — it is the wrong product to be pricing, and a prescriber will not write it for weight alone.

What does each cost without cover?

Tirzepatide by route, monthly and annual
Route	Monthly	Twelve months	Evidence
Commercial cover plus savings card	$25	$300	Provider-reported
Medicare GLP-1 Bridge	$50	$600	Reported
Compounded, 12-month, flat	$186	$2,232	Captured at source
Compounded, month-to-month, flat	$215	$2,580	Captured at source
Brand Zepbound, LillyDirect vials	$299–$449	$4,788	Captured at source
Brand Zepbound, retail pens	~$1,060	~$12,720	Third-party claim

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

Which trials apply to which?

What each pivotal trial established
Trial	Population	Result	Duration
SURMOUNT-1	Obesity or overweight, no diabetes	22.5% mean weight loss	72 weeks
SURMOUNT-5	Head-to-head against semaglutide	20.2% vs 13.7%	72 weeks
SURPASS-2	Type 2 diabetes	Superior HbA1c reduction	40 weeks
SURMOUNT-OSA	Obstructive sleep apnoea with obesity	Large AHI reduction	52 weeks

Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.

SURPASS studied the diabetes population; SURMOUNT studied weight management. Same molecule, different questions, different endpoints. Quoting a SURMOUNT weight figure for a diabetes decision, or the reverse, is the most common error in coverage of these two.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Is Mounjaro the same as Zepbound?

Same active molecule, tirzepatide, from the same manufacturer. They differ in approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and sleep apnoea.

Which is easier to get covered?

Mounjaro, if you have a type 2 diabetes diagnosis — most plans cover diabetes drugs while many still exclude obesity medications.

Can I get Mounjaro for weight loss?

It is not approved for that, and a prescriber will not write it for weight alone. Zepbound is the weight-management approval of the same molecule.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Mounjaro vs Zepbound: Same Molecule, Different Rules.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/mounjaro-vs-zepbound-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.